晚发多发性硬化症患者队列中的治疗反应
Sophie Ahmad1,2, Edith L Graham2, Nicola Lancki3
1Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA.
概括
晚期多发性硬化症 (MS) 治疗的效果有限. 低/中等疗效的疾病修饰疗法 (DMT) 在老年多发性硬化症患者中没有显著改变长期残疾进展.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床研究 临床研究
背景情况:
- 晚发性多发性硬化症 (LOMS) 在临床试验中代表性不足.
- 在LOMS中疾病修饰疗法 (DMT) 的有效性尚未得到充分证实.
- 关于最佳的LOMS治疗策略存在知识差距.
研究的目的:
- 评估复发性LOMS的治疗结果.
- 在LOMS患者中评估DMT的疗效.
- 在LOMS中分析影响残疾进展的因素.
主要方法:
- 追溯电子病历研究.
- 对人口统计,临床,DMT和MRI数据 (2004-2021) 的分析.
- 基于DMT疗效的疾病进展的统计评估.
主要成果:
- 63名LOMS患者 (中位发病55岁) 接受了7.6年的随访.
- 低/中等功效的DMT (LET/MET) 在73%的患者中使用.
- 与没有DMT相比,LET/MET对EDSS 6.0的进展没有显著差异.
结论:
- 低/中等功效的DMT可能在患有LOMS的老年人中影响较小.
- 目前的DMT可能不会显著影响LOMS的长期残疾结果.
- 对于有效的LOMS治疗策略,需要进一步的研究.
相关概念视频
Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drug Therapy
100
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
100
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K


